AbCellera Biologics (ABCL) Institutional Ownership

61.42% of AbCellera Biologics' stock is owned by institutional investors. Learn more on ABCL's institutional investor holdings.

Of the 120 institutional investors that purchased AbCellera Biologics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC ($19.05M), Bank of America Corp DE ($8.91M), Capital World Investors ($7.93M), Goldman Sachs Group Inc. ($4.09M), BlackRock Inc. ($3.81M), Tudor Investment Corp ET AL ($2.53M), and Norges Bank ($2.09M).

Institutional investors have bought a total of 36,693,100 shares in the last 24 months. This purchase volume represents approximately $189.18M in transactions.

Of the 29 institutional investors that sold AbCellera Biologics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ($3.26M), Alyeska Investment Group L.P. ($2.07M), Renaissance Technologies LLC ($1.85M), Millennium Management LLC ($1.62M), UBS Group AG ($1.51M), Jump Financial LLC ($594.33K), and Lazard Asset Management LLC ($346.87K).

Institutional investors have sold a total of 11,889,544 shares in the last 24 months. This volume of shares sold represents approximately $67.90M in transactions.